Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

K2 Summit Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,875,018

162 payments

Through program year 2025, K2 Summit Research LLC is reported as receiving $3,875,018 in research payments, across 162 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $3,515,544 124
2024 Research $320,206 29
2023 Research $39,268 9

Breakdown

Who paid Research payments · program years 2023–2025
  1. Janssen Research & Development, LLC $3,608,271 112 payments
  2. AbbVie, Inc. $128,131 22 payments
  3. GlaxoSmithKline, LLC. $104,326 22 payments
  4. ACADIA Pharmaceuticals Inc $22,750 5 payments
  5. Sanofi Pasteur Inc. $11,540 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $3,608,271 112 payments
  2. A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle $104,326 22 payments
  3. Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $42,562 9 payments
  4. Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $26,604 1 payment
  5. Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $26,111 5 payments
  6. Acp-204-012 $22,750 5 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Subjects with Alzheimer s Disease $21,500 2 payments
  8. A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age $11,540 1 payment
  9. Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease $8,326 2 payments
  10. M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease $2,564 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record